Prospective, Nonrandomized, 36-Month Study of Second-Generation Trabecular Microbypass Stents With Phacoemulsification in Eyes With Various Types of Glaucoma
Hengerer FH, Auffarth GU, Riffel C, Conrad-Hengerer I Ophthalmol Ther. 2018;7:405-415
Study Summary
This prospective, nonrandomized, consecutive cohort study aimed to assess 36-month outcomes after cataract surgery and implantation of two second-generation trabecular microbypass stents (iStent inject) into eyes with various types of glaucoma.
Of the 81 eyes included, 60 had primary open-angle glaucoma (POAG), 15 pseudoexfoliative glaucoma (PEX), four appositional narrow-angle glaucoma, and one each pigmentary or neovascular (secondary) glaucoma. Data were reported as the proportion of eyes that achieved ≥ 20% intraocular pressure (IOP) reduction, IOP ≤ 18 mmHg, and IOP ≤ 15 mmHg, as well as the proportion of eyes achieving a reduction in the number of medications at month 36 vs the preoperative regimen. All subjects were Caucasian and had surgery with a single surgeon in Germany.
At baseline, 32.1% of eyes had undergone previous glaucoma surgery, 56% were receiving three to four preoperative medications, and one eye (1%) was medication-free. Mean preoperative IOP was 22.6 ± 6.2 mm Hg, and mean medication burden was 2.5 ± 1.1 medications. In a subgroup analysis of the preoperative data, patients with POAG were similar to the overall cohort, whereas those with PEX had about a 1 mm Hg higher IOP and a higher mean medication burden, at 2.8 medications. Of the original cohort, not all eyes were followed for the full 36 months. Therefore, some of the postoperative subgroup analyses were performed at 12 months' follow-up.
